Summary of Significant Accounting Policies Summary of Significant Accounting Principles (Tables)

3 Months Ended

Sep. 30, 2026

Schedule of Other Nonoperating Income (Expense)

Other Income, Net

The following table summarizes the components of other income, net.


	Three Months Ended September 30,
		2026		2025
Gains on derivatives not designated as hedging instruments (1)		$	6,554	$	3,451
Currency-related losses, net (2)		(2,817)		(181)
Other gains		2,212		183
Total other income, net		$	5,949	$	3,453

_____________________

(1) Includes realized and unrealized gains and losses on derivative currency forward and option contracts not designated as hedging instruments. For contracts not designated as hedging instruments, we realized losses of $1,136 and $2,692 for the three months ended September 30, 2026 and 2025, respectively. Refer to Note 4 for additional details relating to our derivative contracts.

(2) Currency-related losses, net primarily relates to significant non-functional currency intercompany financing relationships that we may change at times and are subject to currency exchange rate volatility.

Schedule of Weighted Average Number of Shares

The following table sets forth the reconciliation of the weighted-average number of ordinary shares.


	Three Months Ended September 30,
		2026	2025
Weighted-average shares outstanding, basic		24,484,986	24,574,455
Weighted-average shares issuable upon exercise/vesting of outstanding share options/PSUs/RSUs/warrants (1)(2)		—	477,287
Shares used in computing diluted net (loss) income per share attributable to Cimpress plc		24,484,986	25,051,742
Weighted-average anti-dilutive shares excluded from diluted net (loss) income per share attributable to Cimpress plc (1)(2)		1,692,178	1,955,243

__________________

(1) In the periods in which a net loss is recognized, the impact of share options, PSUs, RSUs and warrants is excluded from shares used in computed diluted net loss per share as it is anti-dilutive.

(2) On May 1, 2020, we entered into a financing arrangement which included 7-year warrants to purchase 1,055,377 of our ordinary shares with a strike price of $60. The effect of the warrants on our weighted-average shares outstanding for a period is dilutive if the average market price of our ordinary shares during the period was higher than the strike price of the warrants and anti-dilutive if the average market price of our ordinary shares during the period was lower than the strike price of the warrants.